How India Exports Pazopanib to the World

In the United States, the Food and Drug Administration (FDA) regulates the approval and importation of pharmaceuticals, including pazopanib. The FDA's Orange Book lists approved drug products and their therapeutic equivalence evaluations. As of March 2026, several Abbreviated New Drug Applications (ANDAs) for generic versions of pazopanib have been approved, indicating a competitive market landscape. Notably, the FDA approved an ANDA for a generic version of pazopanib in June 2025, enhancing market competition.

Given that 84.4% of India's pazopanib exports are directed to the United States, it is imperative for Indian exporters to ensure compliance with FDA regulations. This includes adherence to Current Good Manufacturing Practices (cGMP) and maintaining rigorous quality control measures to avoid import alerts or detentions. The presence of 109 active Indian exporters underscores the importance of stringent regulatory compliance to sustain market access.

In the European Union (EU) and the United Kingdom (UK), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively, oversee the approval and monitoring of pharmaceuticals. Pazopanib has been granted marketing authorization in the EU, subject to compliance with EU Good Manufacturing Practice (GMP) standards. Similarly, the MHRA requires adherence to UK GMP regulations for pazopanib marketed within the UK.

While the primary export destinations for Indian-manufactured pazopanib are outside the EU and UK, Indian exporters targeting these markets must ensure compliance with the respective regulatory requirements, including obtaining necessary marketing authorizations and adhering to GMP standards.

The World Health Organization (WHO) maintains the Model List of Essential Medicines (EML), which guides countries in developing their national essential medicines lists. As of the 24th edition published in September 2025, pazopanib is not included in the WHO EML. However, it is essential for exporters to be aware of international pharmacopoeia standards, such as those set by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure global quality compliance.

In India, the Central Drugs Standard Control Organization (CDSCO) classifies pharmaceuticals to regulate their distribution and use. Pazopanib is categorized under Schedule H, indicating that it is a prescription drug requiring a valid prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) oversees drug pricing; however, as of March 2026, pazopanib is not listed under the Drug Price Control Order (DPCO), meaning it does not have a government-mandated ceiling price. For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

Pazopanib was initially patented by GlaxoSmithKline, with the primary patent expiring in 2023. The expiration has led to increased generic competition, as evidenced by the approval of multiple ANDAs by the FDA. This competitive landscape necessitates that Indian exporters focus on maintaining high-quality standards and cost-effective production to remain competitive in the global market.

In June 2025, the FDA approved an ANDA for a generic version of pazopanib, signaling increased competition in the U.S. market. In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, which did not include pazopanib. In October 2025, the NPPA conducted a review of oncology drug prices, though pazopanib remained outside the purview of price control under the DPCO. In December 2025, the EMA issued updated guidelines on GMP compliance for manufacturers exporting to the EU, emphasizing the need for stringent quality control measures. In February 2026, the CDSCO announced a streamlined process for obtaining export NOCs, aiming to facilitate pharmaceutical exports while ensuring regulatory compliance.

These developments underscore the dynamic nature of the regulatory landscape for pazopanib. Indian exporters must stay abreast of regulatory changes and market dynamics to ensure continued access to key markets and maintain a competitive edge.

Pazopanib, an antineoplastic agent primarily used in the treatment of renal cell carcinoma, relies heavily on Active Pharmaceutical Ingredients (APIs) manufactured in India. However, the production of these APIs is intricately linked to Key Starting Materials (KSMs) and intermediates, a significant portion of which are imported from China. This dependency poses a strategic chokepoint in the supply chain, as any disruption in the availability of these KSMs can halt API synthesis, leading to potential shortages of the final pharmaceutical product.

Recent analyses have highlighted the vulnerabilities associated with this reliance. A report from the U.S. Pharmacopeia in October 2025 indicated that 58% of KSMs used for U.S.-approved APIs are sourced from a single country, with China accounting for 41% and India for 16%. This concentration underscores the risk of supply chain disruptions due to geopolitical tensions, trade restrictions, or manufacturing issues in these countries.

Our proprietary trade data from 2022 to 2026 reveals a significant concentration in the export of Pazopanib from India. The top five exporters account for 77.0% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 66.6% ($5.6 million USD). This high level of supplier concentration introduces a substantial single-source risk; any operational or compliance issues within these leading firms could severely impact the global supply of Pazopanib.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are crucial for antibiotic production. While these initiatives are steps toward enhancing domestic production capabilities, their direct impact on the Pazopanib supply chain remains to be seen.

The global pharmaceutical supply chain is susceptible to various geopolitical and logistical challenges. Tensions in critical maritime routes such as the Red Sea and the Strait of Hormuz can disrupt shipping lanes, leading to delays and increased transportation costs for raw materials and finished products. Additionally, ongoing U.S.-China trade disputes have the potential to affect the availability and pricing of KSMs sourced from China, further exacerbating supply chain vulnerabilities.

Regulatory bodies have acknowledged these risks. In January 2025, the FDA emphasized the importance of proactive measures to prevent and mitigate medical device shortages, highlighting the need for manufacturers to notify the agency of potential supply disruptions. Similarly, the European Medicines Agency (EMA) has been actively monitoring medicine shortages and working to coordinate responses to critical supply issues. (ema.europa.eu)

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different geographies to reduce dependency on a single source or region.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical KSMs and intermediates to decrease reliance on imports, particularly from high-risk regions.

• Strengthen Regulatory Compliance: Implement robust quality control and compliance programs to minimize the risk of regulatory actions that could disrupt supply chains.

• Develop Contingency Plans: Establish comprehensive risk management strategies, including maintaining buffer stocks and identifying alternative logistics routes to mitigate potential disruptions.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that could impact the pharmaceutical supply chain, allowing for timely adjustments to sourcing and distribution strategies.

RISK_LEVEL: MEDIUM